Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Structural basis for the resilience of efavirenz (DMP-266) to drug resistance mutations in HIV-1 reverse transcriptase.

Structure (London, England : 1993) - 15 Oct 2000

Ren J, Milton J, Weaver K L, Short S A, Stuart D I, Stammers D K

Abstract excerpt

BACKGROUND: Efavirenz is a second-generation non-nucleoside inhibitor of HIV-1 reverse transcriptase (RT) that has recently been approved for use against HIV-1 infection. Compared with first-generation drugs such as nevirapine, efavirenz shows greater resilience to drug resistance mutations within HIV-1 RT. In order to understand the basis for this resilience at the molecular level and to help the design of...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Alkynes
Share to Anti-HIV Agents
Share to Benzoxazines

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cyclopropanes

Share to HIV Reverse Transcriptase

Share to Nevirapine

Share to Oxazines

Share to Reverse Transcriptase Inhibitors

Source

Identifiers

PMID: 11080630
DOI: 10.1016/s0969-2126(00)00513-x

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Structural basis for the resilience of efavirenz (DMP-266) to drug resistance mutations in HIV-1 reverse transcriptase.PMID 11080630Read ↗

Structural Aspects of Drug Resistance and Inhibition of HIV-1 Reverse TranscriptaseSemantic proximity Read ↗

Structural basis for the inhibitory efficacy of efavirenz (DMP-266), MSC194 and PNU142721 towards the HIV-1 RT K103N mutant.Semantic proximity Read ↗

Characterization and Structural Analysis of Novel Mutations in Human Immunodeficiency Virus Type 1 Reverse Transcriptase Involved in the Regulation of Resistance to Nonnucleoside InhibitorsSemantic proximity Read ↗

Unraveling the Mechanism of HIV-1 Hypersusceptibility to Tenofovir Imparted by Islatravir Resistance MutationsSemantic proximity Read ↗

Relationship of potency and resilience to drug resistant mutations for GW420867X revealed by crystal structures of inhibitor complexes for wild-type, Leu100Ile, Lys101Glu, and Tyr188Cys mutant HIV-1 reverse transcriptases.Semantic proximity Read ↗

Crystal structures of HIV-1 reverse transcriptases mutated at codons 100, 106 and 108 and mechanisms of resistance to non-nucleoside inhibitors.Semantic proximity Read ↗

Small Conformational Changes Underlie Evolution of Resistance to NNRTI in HIV Reverse Transcriptase.Semantic proximity Read ↗

Investigating the mutation resistance of nonnucleoside inhibitors of HIV-RT using multiple microsecond atomistic simulations.Semantic proximity Read ↗

Design of non-nucleoside inhibitors of HIV-1 reverse transcriptase with improved drug resistance properties. 1.Semantic proximity Read ↗

Drug resistance mutations in the nucleotide binding pocket of human immunodeficiency virus type 1 reverse transcriptase differentially affect the phosphorolysis-dependent primer unblocking activity in the presence of stavudine and zidovudine and its inhibition by efavirenz.Semantic proximity Read ↗

Structural basis for the resilience of Darunavir (TMC114) resistance major flap mutations of HIV-1 protease.Semantic proximity Read ↗

Efavirenz.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.